The VRFCAT is a new virtual reality measure that estimates patients’ ability to go through daily challenges using realistic, simulated environments.
NeuroCog Trials had finished phase I of the project to develop VRFCAT in collaboration with Virtual Heroes.
NeuroCog Trials founder and chief executive officer Richard Keefe said following the VRFCAT success, NeuroCog set out to secure additional funding to support its validation and commercialization.
”We aim for the VRFCAT to be used as a reliable tool in clinical trials to measure changes in functional capacity associated with the pro-cognitive effects of novel drugs for schizophrenia, bipolar disorder, Alzheimer’s disease and other diseases," Keefe added.
NeuroCog president Caren Gadigian said, " The VRFCAT expands our assessment portfolio from traditional paper and pencil neurocognitive measures and our Computerized Brief Assessment of Cognition in Schizophrenia (C-BACS) developed for the iPad® platform, to now include this virtual reality tool."
NIH funding will support virtual reality measure to evaluate the pro-cognitive effects of new medicines.